Many deals that create potential antitrust problems can be approved with a “remedy,” such as a divestiture of a business unit or a set of assets, which will fix the competitive problem identified by the government during the merger review process.
In fiscal year 2015, of the 42 deals that the U.S. Federal Trade Commission or Department of Justice Antitrust Division believed would violate the antitrust laws, 25 of them — approximately 60 percent — were allowed to proceed pursuant to a remedy.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
